138 related articles for article (PubMed ID: 31216345)
1. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
Bjune K; Wierød L; Naderi S
PLoS One; 2019; 14(6):e0218537. PubMed ID: 31216345
[TBL] [Abstract][Full Text] [Related]
2. MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent.
Bjune K; Sundvold H; Leren TP; Naderi S
Atherosclerosis; 2018 Sep; 276():28-38. PubMed ID: 30025252
[TBL] [Abstract][Full Text] [Related]
3. Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA.
Bjune K; Wierød L; Naderi S
Sci Rep; 2018 Nov; 8(1):16174. PubMed ID: 30385871
[TBL] [Abstract][Full Text] [Related]
4. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Yamaji M; Ota A; Wahiduzzaman M; Karnan S; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y; Haniuda M
Cancer Med; 2017 Nov; 6(11):2646-2659. PubMed ID: 28960945
[TBL] [Abstract][Full Text] [Related]
5. Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA.
Sundvold H
Molecules; 2020 Oct; 25(19):. PubMed ID: 33019656
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
8. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
9. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
Guo JP; Coppola D; Cheng JQ
J Biol Chem; 2011 Oct; 286(43):37389-98. PubMed ID: 21908616
[TBL] [Abstract][Full Text] [Related]
10. Development of a new model system to dissect isoform specific Akt signalling in adipocytes.
Kajno E; McGraw TE; Gonzalez E
Biochem J; 2015 Jun; 468(3):425-34. PubMed ID: 25856301
[TBL] [Abstract][Full Text] [Related]
11. Akt Pathway Inhibitors.
Uko NE; Güner OF; Matesic DF; Bowen JP
Curr Top Med Chem; 2020; 20(10):883-900. PubMed ID: 32091335
[TBL] [Abstract][Full Text] [Related]
12. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
14. Blockage of the ERK signaling pathway abrogates the SCAP ligand-induced transcriptional activation of the LDL receptor gene in HepG2 cells.
Abidi P; Zhang F; Li C; Liu J
Int J Mol Med; 2005 Nov; 16(5):779-85. PubMed ID: 16211244
[TBL] [Abstract][Full Text] [Related]
15. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
16. Nonsense-mediated decay of human LDL receptor mRNA.
Holla ØL; Kulseth MA; Berge KE; Leren TP; Ranheim T
Scand J Clin Lab Invest; 2009; 69(3):409-17. PubMed ID: 19148831
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins.
Yashiro T; Nanmoku M; Shimizu M; Inoue J; Sato R
Atherosclerosis; 2012 Feb; 220(2):369-74. PubMed ID: 22153697
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
[TBL] [Abstract][Full Text] [Related]
19. CCT128930 induces cell cycle arrest, DNA damage, and autophagy independent of Akt inhibition.
Wang FZ; Chang ZY; Fei HR; Yang MF; Yang XY; Sun BL
Biochimie; 2014 Aug; 103():118-25. PubMed ID: 24793486
[TBL] [Abstract][Full Text] [Related]
20. A novel peroxisome proliferator response element modulates hepatic low-density lipoprotein receptor gene transcription in response to PPARδ activation.
Shende VR; Singh AB; Liu J
Biochem J; 2015 Dec; 472(3):275-86. PubMed ID: 26443862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
